Outcome of pars plana vitrectomy with pre-operative intra vitreal bevacizumab in diabetic patients with vitreous haemorrhage

Authors

  • Alina Mustafa Ophthalmology Department, Services Hospital Lahore
  • Saqib Siddiq Ophthalmology Department, Services Hospital Lahore
  • Maha Shahbaz Ophthalmology Department, Services Hospital Lahore
  • Khawaja Mohsin Ihsan Ophthalmology Department, Services Hospital Lahore
  • Syed Raza Ali Shah Ophthalmology Department, Eye Unit 2, Jinnah Hospital Lahore
  • Khalid Waheed Ophthalmology Department, Services Hospital Lahore

DOI:

https://doi.org/10.37018/XATM1361

Keywords:

Intravitreal Bevacizumab, vitreous hemorrhage, vitrectomy, advanced diabetic eye disease

Abstract

Background: Intravitreal bevacizumab causes regression of retinal neo vessels in proliferative diabetic retinopathy as it is anti-vascular endothelial growth factor (anti VEGF). So this study was done to observe the effect of pre-operative intravitreal bevacizumab on intra operative outcome when administered in patients with vitreous hemorrhage undergoing pars-plana vitrectomy (PPV).
Patients and methods: This quasi-experimental trial was carried out in the Department of Ophthalmology Services Hospital Lahore from June 2020 to December 2020. Fifty seven diabetic patients with vitreous hemorrhage were selected who were eligible for PPV. Patients with recurrent hemorrhage were not included. Demographics were recorded and all patients were given intravitreal bevacizumab (1.25 mg/0.05 ml) one week prior to vitrectomy and intra-operative bleeding was noted. Intra-operative bleeding was graded as No, Mild and Severe bleeding.
Results: The mean age of patients undergoing PPV was 55.36 ± 4.62 years. There were 35 (61%) males and 22 (39%) females. The mean duration of diabetes was 10.35±1.92 years. Out of 57 eyes, 36 (63.15%) had no bleeding, 11 (19.29%) had mild and 10 (17.54%) had severe intra-operative bleeding.
Conclusion: Intravitreal bevacizumab prior to PPV is quite effective in reducing the risk of intra-operative bleeding in patients with vitreous hemorrhage.

Downloads

Published

2022-04-04

How to Cite

1.
Mustafa A, Siddiq S, Shahbaz M, Ihsan KM, Shah SRA, Waheed K. Outcome of pars plana vitrectomy with pre-operative intra vitreal bevacizumab in diabetic patients with vitreous haemorrhage. J Fatima Jinnah Med Univ [Internet]. 2022 Apr. 4 [cited 2024 May 5];15(3):132-5. Available from: https://www.jfjmu.com/index.php/ojs/article/view/818

Issue

Vol. 15 No. 3 (2021): Journal of Fatima Jinnah Medical University

Section

Articles

License

The Journal of Fatima Jinnah Medical University follows the Attribution Creative Commons-Non commercial (CC BY-NC) license which allows the users to copy and redistribute the material in any medium or format, remix, transform and build upon the material. The users must give credit to the source and indicate, provide a link to the license, and indicate if changes were made. However, the CC By-NC license restricts the use of material for commercial purposes. For further details about the license please check the Creative Commons website. The editorial board of JFJMU strives hard for the authenticity and accuracy of the material published in the journal. However, findings and statements are views of the authors and do not necessarily represent views of the Editorial Board.